CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer

Haineng Xu; Sarah B. Gitto; Gwo-Yaw Ho; Sergey Medvedev; Kristy Shield-Artin; Hyoung Kim; Sally Beard; Yasuto Kinose; Xiaolei Wang; Holly E. Barker; Gayanie Ratnayake; Wei-Ting Hwang; Ryan J. Hansen; Bryan Strouse; Snezana Milutinovic; Christian Hassig; Matthew J. Wakefield; Cassandra J. Vandenberg; Clare L. Scott; Fiona Simpkins

iScience (Jul 2024)

CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer

Haineng Xu,
Sarah B. Gitto,
Gwo-Yaw Ho,
Sergey Medvedev,
Kristy Shield-Artin,
Hyoung Kim,
Sally Beard,
Yasuto Kinose,
Xiaolei Wang,
Holly E. Barker,
Gayanie Ratnayake,
Wei-Ting Hwang,
Ryan J. Hansen,
Bryan Strouse,
Snezana Milutinovic,
Christian Hassig,
Matthew J. Wakefield,
Cassandra J. Vandenberg,
Clare L. Scott,
Fiona Simpkins

Affiliations

Haineng Xu: Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Sarah B. Gitto: Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Gwo-Yaw Ho: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia
Sergey Medvedev: Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Kristy Shield-Artin: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia
Hyoung Kim: Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Sally Beard: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
Yasuto Kinose: Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Xiaolei Wang: Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Holly E. Barker: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia
Gayanie Ratnayake: The Royal Women’s Hospital, Parkville, VIC 3052, Australia
Wei-Ting Hwang: Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA
Ryan J. Hansen: Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia
Bryan Strouse: Sierra Oncology, Inc, 885 West Georgia Street, Suite 2150, Vancouver, BC V6C 3E8, Canada
Snezana Milutinovic: Sierra Oncology, Inc, 885 West Georgia Street, Suite 2150, Vancouver, BC V6C 3E8, Canada
Christian Hassig: Sierra Oncology, Inc, 885 West Georgia Street, Suite 2150, Vancouver, BC V6C 3E8, Canada
Matthew J. Wakefield: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3010, Australia
Cassandra J. Vandenberg: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia
Clare L. Scott: The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia; The Royal Women’s Hospital, Parkville, VIC 3052, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3010, Australia; Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia; Corresponding author
Fiona Simpkins: Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Corresponding author

Journal volume & issue: Vol. 27, no. 7
p. 109978

Abstract

Read online

Summary: High-grade serous ovarian cancers (HGSOCs) with homologous recombination deficiency (HRD) are initially responsive to poly (ADP-ribose) polymerase inhibitors (PARPi), but resistance ultimately emerges. HGSOC with CCNE1 amplification (CCNE1amp) are associated with resistance to PARPi and platinum treatments. High replication stress in HRD and CCNE1amp HGSOC leads to increased reliance on checkpoint kinase 1 (CHK1), a key regulator of cell cycle progression and the replication stress response. Here, we investigated the anti-tumor activity of the potent, highly selective, orally bioavailable CHK1 inhibitor (CHK1i), SRA737, in both acquired PARPi-resistant BRCA1/2 mutant and CCNE1amp HGSOC models. We demonstrated that SRA737 increased replication stress and induced subsequent cell death in vitro. SRA737 monotherapy in vivo prolonged survival in CCNE1amp models, suggesting a potential biomarker for CHK1i therapy. Combination SRA737 and PARPi therapy increased tumor regression in both PARPi-resistant and CCNE1amp patient-derived xenograft models, warranting further study in these HGSOC subgroups.

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords